Compare PCRX & NABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | NABL |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.0M | 825.1M |
| IPO Year | 2010 | 2021 |
| Metric | PCRX | NABL |
|---|---|---|
| Price | $25.96 | $4.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $30.25 | $8.31 |
| AVG Volume (30 Days) | 479.1K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | $511,430,000.00 |
| Revenue This Year | $6.78 | $11.04 |
| Revenue Next Year | $8.54 | $8.53 |
| P/E Ratio | $370.43 | ★ N/A |
| Revenue Growth | ★ 26.04 | 9.71 |
| 52 Week Low | $18.80 | $2.92 |
| 52 Week High | $27.64 | $9.04 |
| Indicator | PCRX | NABL |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 49.34 |
| Support Level | $21.89 | $3.24 |
| Resistance Level | $26.94 | $4.29 |
| Average True Range (ATR) | 0.82 | 0.32 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 56.59 | 27.52 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.